Compare Prologis Inc (PLD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Prologis Inc trades at $129.7 (market cap $122.87B), while State Street SPDR S&P Biotech ETF trades at $153.82 (market cap $10.11B). The key difference: Prologis Inc is far larger — about 12.2× State Street SPDR S&P Biotech ETF's market cap, and Prologis Inc pays a 3.31% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| PLD | XBI | |
|---|---|---|
Market Cap | $122.87B | $10.11B |
Volume | 4,222,957 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $149.96 | $169.55 |
52-Week Low | $111.23 | $104.99 |
Typical Hold Time | 102 Days | 38 Days |
Enterprise Value | $157.61B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $129.18, up 1.48% today, with a bearish technical signal but strong fundamentals. The stock faces near-term resistance at $130, with support at $127. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $1.13 versus $0.747 expected. Revenue grew to $8.79B in 2025, and net income margin remains robust at 45.79%. The company benefits from strong warehouse demand driven by e-commerce and data centers, as highlighted in recent news.
Outlook is positive with a consensus price target of $155.15, implying 20% upside, supported by 59.5% analyst buy ratings. Risks include rising debt-to-asset ratio (37.2% in 2025) and macroeconomic sensitivity. Institutional interest is strong, with QRG Capital increasing holdings by 11% in Q2 2026. The dividend yield of approximately 0.83% adds income appeal, but investors should monitor leverage and interest rate impacts.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
